SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.73
+3.68%Year over year
Reported trailing growth
- Revenue
- -20.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +71.0%
- Operating cash flow
- +69.5%
Forward estimates
Based on analyst estimates
- Revenue
- -28.7%
- EBITDA
- +1227.7%
- EPS
- +125.1%
Three-year CAGR
- Revenue
- +33.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +12.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026